Recently, Marsodetide, a novel drug independently developed in China, has been featured in the prestigious international medical journal The Lancet due to its remarkable efficacy in treating obesity and type 2 diabetes. Co-developed by Innovent Biologics and Eli Lilly, Marsodetide is a long-acting dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. By simultaneously activating both receptors, it effectively regulates blood glucose, suppresses appetite, and promotes weight loss.Clinical trial data from a 48-week Phase III study showed that patients treated with Marsodetide achieved an average body weight reduction of over 15%, with significantly better glycemic control compared to the placebo group and manageable adverse effects. This milestone not only represents a major breakthrough for China in the field of metabolic disease drug innovation but also highlights the growing global competitiveness of domestic biopharmaceutical companies.Experts note that Marsodetide offers a promising new therapeutic option for hundreds of millions of patients worldwide suffering from obesity and diabetes, potentially becoming another blockbuster metabolic drug following semaglutide. The drug has already been submitted for marketing approval in China and is planned for regulatory filings in multiple countries globally.
近日，中国自主研发的创新药玛仕度肽（Marsodetide）因其在治疗肥胖和2型糖尿病方面的显著疗效，成功登上国际顶级医学期刊《柳叶刀》（The Lancet）。该药物由信达生物与礼来公司联合开发，是一种长效GLP-1/GIP双受体激动剂，通过同时激活胰高血糖素样肽-1（GLP-1）和葡萄糖依赖性促胰岛素多肽（GIP）受体，有效调控血糖、抑制食欲并促进体重下降。临床试验数据显示，在为期48周的III期研究中，接受玛仕度肽治疗的患者平均体重减轻超过15%，且血糖控制显著优于安慰剂组，不良反应可控。这一成果不仅标志着中国在代谢性疾病创新药研发领域取得重大突破，也彰显了本土生物医药企业走向全球舞台的能力。专家指出，玛仕度肽的成功为全球数亿肥胖及糖尿病患者提供了新的治疗选择，有望成为继司美格鲁肽之后又一重磅代谢类药物。目前，该药已在中国提交上市申请，并计划在全球多国开展注册申报。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/14509.html